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Background: Central line-associated bloodstream infections (CLABs) have long been associated with excess lengths
of stay, increased hospital costs and mortality attributable to them. Different studies from developed countries have
shown that practice bundles reduce the incidence of CLAB in intensive care units. However, the impact of the
bundle strategy has not been systematically analyzed in the adult intensive care unit (ICU) setting in developing
countries, such as Turkey. The aim of this study is to analyze the impact of the International Nosocomial Infection
Control Consortium (INICC) multidimensional infection control approach to reduce the rates of CLAB in 13 ICUs of
13 INICC member hospitals from 8 cities of Turkey.
Methods: We conducted active, prospective surveillance before-after study to determine CLAB rates in a cohort of
4,017 adults hospitalized in ICUs. We applied the definitions of the CDC/NHSN and INICC surveillance methods. The
study was divided into baseline and intervention periods. During baseline, active outcome surveillance of CLAB rates
was performed. During intervention, the INICC multidimensional approach for CLAB reduction was implemented and
included the following measures: 1- bundle of infection control interventions, 2- education, 3- outcome surveillance,
4- process surveillance, 5- feedback of CLAB rates, and 6- performance feedback on infection control practices. CLAB
rates obtained in baseline were compared with CLAB rates obtained during intervention.
Results: During baseline, 3,129 central line (CL) days were recorded, and during intervention, we recorded 23,463
CL-days. We used random effects Poisson regression to account for clustering of CLAB rates within hospital across time
periods. The baseline CLAB rate was 22.7 per 1000 CL days, which was decreased during the intervention period to
12.0 CLABs per 1000 CL days (IRR 0.613; 95% CI 0.43 – 0.87; P 0.007). This amounted to a 39% reduction in the
incidence rate of CLAB.
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Conclusions: The implementation of multidimensional infection control approach was associated with a significant
reduction in the CLAB rates in adult ICUs of Turkey, and thus should be widely implemented.
Keywords: Catheter related infections, Central line-associated bloodstream infection, Device-associated infections,
Healthcare-associated infections, Bundle, International nosocomial infection control consortium, Multidimensional
approach, Hand hygiene, Developing countries, Limited-resource countriesBackground
The burden of central line-associated bloodstream infec-
tion (CLAB) in critically ill patients has been widely
addressed in the scientific literature worldwide. According
to studies from developed [1] and developing countries
[2,3], including Turkey [4], the most serious clinical conse-
quences attributable to CLAB are increased mortality rates
[1], significant morbidity [1], and increased LOS [2,5,6].
From an economic perspective, CLABs are also respon-
sible for significant increases in healthcare costs, as
reported in both developed [1] and developing countries
[2,5], but there are not available published data on costs of
CLAB from Turkey.
The results reported from hospitals members of the
International Nosocomial Infection Control Consortium
(INCC) revealed that device-associated healthcare-acquired
infections (DA-HAI) rates in the intensive care units (ICUs)
of limited-resources countries are 3 to 5 times higher than
rates in the ICUs of high-income countries [7-10]. How-
ever, most hospitals in limited-resource countries do not
implement basic infection control programs, resulting in a
general unawareness of the incidence of CLAB at their
healthcare facilities [11].
In addition, the socio-economic level of a country and
hospital type were reported to have an impact on DA-HAI
rates in the ICU settings of developing countries in two
studies [12,13]. As regards hospital type, CLAB rates in
neonatal ICUs from public and academic hospitals were
significantly higher than in private hospitals: 14.3 and 14.6
vs.10.8 CLABs per 1000 CL-days [12]. With regard to the
country socioeconomic level, in a study conducted in
pediatric ICUs it was shown that lower-middle-income
countries had higher CLAB rates than upper middle-
income countries (12.2 vs. 5.5 per 1000 CL-days) [13].
Similarly, CLAB rates in neonatal ICUs were shown to be
higher in low-income countries than in lower-middle and
upper-middle-income countries [12].
In the developed countries, it has been demonstrated
that surveillance is fundamental to prevent CLABs, which
can be reduced by more than 30% [14]. Implementing in-
fection control bundles alone—including five interven-
tions, such as 1- hand hygiene, 2- skin antisepsis with
chlorhexidine, 3- maximal barriers, 4- insertion in sub-
clavian vein, and 5 - timely central line (CL) removal—were associated with a reduction in the incidence density
of CLAB in developed countries [15].
INICC supports hospitals in limited-resource countries in
performing surveillance and reducing healthcare-associated
infection rates. Hospitals from limited-resource countries
contact INICC and then receive forms and manuals with
guidance to implement effective surveillance and infection
control programs. INICC also provides administrative and
scientific support to upload, process, analyze and create
charts and tables with the collected data.
With the aim of reducing these high CLAB rates, we
implemented a multidimensional infection control pro-
gram—which included specific interventions for CLAB
prevention, such as a practice bundle, education, outcome
surveillance, process surveillance, feedback of CLAB rates,
as well as performance feedback of infection control prac-
tices—in 13 adult ICUs of 13 hospitals, in 8 cities of
Turkey. The implementation of the INICC multidimen-
sional program for CLAB prevention is based on the rec-
ommendations and guidelines published by the Society for
Health Care Epidemiology of America (SHEA) and the In-
fectious Diseases Society of America (IDSA) in 2008 [16].
This study analyses the particular effect of this pre-
ventive multidimensional strategy on CLAB rates in the
adult ICU setting of Turkey from September 2003 to
January 2011.
Methods
Setting and study design
From September 2003 to January 2011, we conducted an
active, prospective outcome and process surveillance
before-after study in 13 Intensive Care Units (ICUs) in
13 hospitals members of the INICC in 8 cities of Turkey.
Each hospital had been actively participating in the
INICC Surveillance Program for at least 4 months. Every
hospital had an infection control team (ICT) comprised
of at least a medical doctor with formal education and
background in internal medicine, critical care, infectious
diseases, and/or hospital epidemiology, and infection
control professionals (ICPs).
The study was divided in 2 periods: baseline period
and intervention period.
The Institutional Review Board at each hospital ap-
proved the study protocol.
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The baseline period included only the performance of out-
come surveillance and process surveillance. The length of
the baseline period is three months due to the following
three reasons:
1. This is the time needed to conduct the following
activities at INICC headquarters (HQs) in Argentina
on a monthly basis: receiving those case report
forms (CRF) filled at all participating ICUs from
Turkey; conducting a validation process of filled
CRFs; sending queries to participating ICUs;
receiving and analyzing replies to queries; uploading
CRFs data with proprietary INICC software in
Argentina; analyzing uploaded data; producing
monthly reports containing charts and tables with
the results of outcome and process surveillance;
sending monthly reports to each ICUs; presenting
the monthly report of outcome and process
surveillance data to health care workers (HCWs)
working at the participating ICUs in monthly
infection control meetings, with the aim of
providing feedback on CLAB rates and
consequences and performance feedback and
increase the awareness about CLABs to improve
compliance with infection control practices.
2. Sample size of patients and number of months of
data collection during baseline period is sufficient
enough to compare with sample size of patients and
number of months of data collection during
intervention period. From a statistical perspective,
the issue is addressed by considering the changes in
rates over time. The relatively short baseline period
may impact the standard error of our estimates. But
we found that this will not cause a bias in the
results, because there will not be systematic
differences between the two groups.
3. Our priority is to start intervention as early as possible
in order to achieve the desired results, such as CLAB
rate and mortality rate reduction, as soon as possible.
Intervention period
The intervention period was initiated after three months of
participation in the INICC outcome and process surveil-
lance program. This is a cohort study, and for that reason,
each ICU joined INICC program at different moments.
Thus, by the time we analyzed the impact of the INICC
intervention, we had ICUs with different lengths of inter-
vention periods. The average length of the intervention
period was 15.6 months ± SD 9.2 (range 4 – 36).
INICC multidimensional infection control approach
The INICC multidimensional infection control ap-
proach includes the following: 1- bundle of infectioncontrol interventions, 2- education, 3- outcome surveil-
lance, 4- process surveillance, 5- feedback of CLAB
rates, and 6- performance feedback of infection control
practices.
Components of central line-care bundle for CLAB
1. Perform hand hygiene before CL insertion or
manipulation [17].
2. Use sterile gauze or transparent sterile dressing to
cover insertion site [16].
3. Maintain good condition of sterile dressing. Change
gauze every 48 hours and transparent dressing every
7 days [16].
4. Remove CL as early as possible, when not
necessary [16].
5. Change administration set every 96 hours; unless
used for fat, nutrition or blood precuts, and in this
cases changed every 24 hours [16].
6. Use a chlorhexidine-based antiseptic for skin
preparation [16].
7. Preferably use subclavian vein [16].
8. Use an all-inclusive catheter cart or kit [18].
9. Use maximal sterile barrier precautions during
CL insertion [16].
10. Avoid using several times those vials meant to
be use only once [16].
11. Disinfect line hubs, needleless connectors,
and infection ports before accessing the CL [16].
Some other effective interventions were discussed, but
not applied because of budget limitations; namely, the
following five (5) practices were partially applied or not
applied:
1. Use of split septum instead of mechanical valves or
three ways stopcock [16].
2. Use of chlorhexidine impregnated sponge at insertion
site [16].
3. Daily bath with chlorhexidine [16].
4. Use of antimicrobial impregnated catheters [16].
5. Use of closed collapsible flexible containers instead
of open semi-rigid vented or glass vented IV
containers [19].
Education
Monthly sessions of education provided by ICP to the
HCWs in charge of the insertion, care, and maintenance
of CLs for CLAB prevention based on SHEA and IDSA
guidelines to prevent CLAB [16].
INICC surveillance methods
The INICC Surveillance Program includes two compo-
nents: outcome surveillance (DA-HAI rates and their
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surveillance (adherence to hand hygiene and other basic
preventive infection control practices) [20].
Investigators were required to complete outcome and
process surveillance forms at their hospitals, which were
then sent to the INICC headquarters office in Buenos
Aires, for their monthly analysis.Outcome surveillance
Outcome Surveillance included rates of CLAB per 1000
CL-days, use of invasive devices (CL, mechanical ventila-
tor, and urinary catheter), severity illness score, underlying
diseases, use of antibiotics, culture taken, microorganism
profile, bacterial resistance, length of stay, mortality in
their ICUs [20].
CLAB definitions and surveillance methods were per-
formed applying the definitions for healthcare-associated
infection (HAI) developed by the U.S. Centers for Disease
Control and Prevention (CDC) for the National Healthcare
Safety Network (NHSN) program [21]. In limited-resource
countries, the usual practice is taking blood cultures after
starting antibiotic treatment, or not taking blood cultures
at all. This results in having patients with CLAB but with-
out laboratory evidence of CLAB. For that reason, we de-
cided to continue using “clinical sepsis” as well as
“laboratory confirmed bloodstream infections” as defin-
ition criteria for “CLAB”, as historically used by the CDC
NNIS [22].
Additionally, INICC methods were adapted to the
limited-resource setting of developing countries, due to
their different socioeconomic status [20]. ASIS score was
used instead of APACHE II score due to budget limita-
tions of participating ICUs from this limited-resource
country. Thus, we decided to use ASIS score, as historic-
ally used by the CDC NNIS [22].Definitions
Laboratory confirmed CLAB
When CLAB is suspected, the CL is removed aseptically
and the distal 5 cm of the catheter is amputated and cul-
tured, using the standardized semi quantitative method
[21,22]. Concomitant blood cultures are drawn percutan-
eously in most cases. In each hospital, standard laboratory
methods are used to identify microorganisms, and stan-
dardized susceptibility testing is performed [21,22]. A pa-
tient with a CL who has a recognized pathogen isolated
from one or more percutaneous blood cultures after
48 hours of catheterization; the pathogen cultured from
the blood is not related to an infection at another site; and
patient has one or more of the following signs or symp-
toms: fever (≥38°C), chills, or hypotension. With skin com-
mensals (diphtheroids, Bacillus spp., Propionibacterium
spp., coagulase-negative staphylococci or micrococci), theorganism has been recovered from two or more separate
blood cultures [21-23].
Clinically suspected CL-associated bloodstream infection
A patient with a CL who has at least one of the follow-
ing clinical signs, with no other recognized cause: fever
(≥38°C), hypotension (systolic blood pressure ≤90 mmHg)
or oliguria (≤20 mL/hr), but blood cultures were either
not obtained or no organisms were recovered from blood
cultures; there is no apparent infection at another site; and
the physician institutes antimicrobial therapy [21,22].
Process surveillance
Process surveillance was designed to assess compliance
with easily measurable key infection control practices,
such as surveillance of compliance rates for hand hy-
giene practices and specific measures for the prevention
of CLAB [20].
Because of budget limitations, only five out of eleven
components of the bundle were monitored:
1. Hand hygiene (HH) compliance rate was based on
the frequency with which HH was performed as
indicated in HCWs infection control training.
Observing ICPs were trained to record HH
opportunities and compliance on a form, during
randomly selected observation periods of 30 minutes
to 1 hour, 3 times a week. In particular, the INICC
direct observation comprised the “Five Moments for
Hand Hygiene” as recommended by the World
Health Organization (WHO). The “Five Moments”
included the monitoring of the following moments:
(1) before patient contact, (2) before an aseptic task,
(3) after body fluid exposure risk, (4) after patient
contact, and (5) after contact with patient
surroundings [24]. Although HCWs knew that hand
hygiene practices were regularly monitored, they
were not informed of the schedule for HH
observations.
2. Data on compliance with CL-care measures were
recorded 5 days a week on a form that evaluated if
infection control procedures were correctly carried out
by the HCW. The ICP observing the activity in the
AICU filled a standardized form that contained the
following data: total number of inserted CLs for each
patient for the whole ICU; total number of dressing
placed to protect the puncture site in order to evaluate
number of patients with sterile dressing [20].
3. Also the ICP filled a standardized form that
contained total number of dressings in correct
condition, evaluating if the dressing was clean, dry
and correctly adhered to the puncture site, so as
to evaluate number of dressing in correct
condition [20].
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contained total number of cases in which the dates
in the administration set were written, with the aim
of measuring the number of patients with number of
days of the administration set in place, and
evaluating if the set was replaced by or before
96 hours [20].
5. Finally, the ICP filled a standardized form including
the date of insertion and removal of each CL, to
evaluate number of days of CL inserted, and the
earliest possible removal CL when not necessary.
Feedback of DA-HAI rates
Upon processing the hospitals’ outcome surveillance
data on a monthly basis, the INICC Research Team, at
INICC Headquarters located in Buenos Aires, prepares
and sends to each ICT a final report on the results of
outcome surveillance rates; that is, monthly DA-HAI
rates, length of stay, bacterial profile and resistance, and
mortality [20].
Feedback of DA-HAI rates is provided to HCWs work-
ing in the AICU by communicating the outcomes of the
patients. The resulting rates are reviewed by the ICT at
monthly meetings, where charts are analyzed, and statis-
tical graphs and visuals are posted inside the ICU, to pro-
vide an overview of rates of DA-HAIs. This infection
control tool is key to increase awareness about outcomes
of patients at their ICU, enable the ICT and ICU staff to
focus on the necessary issues and apply specific strategies
for improvement of high DA-HAI rates.
Performance feedback
Upon processing the hospitals’ process surveillance data
on a monthly basis, the INICC Research Team, at INICC
Headquarters located in Buenos Aires, prepares and
sends to each ICT a final report on the results of process
surveillance rates, including compliance with hand hy-
giene, and care of CL [20].
Performance feedback is provided to HCWs working
in the AICU by communicating the assessment of prac-
tices routinely performed by them. The resulting rates
are reviewed by the ICT at monthly meetings, where
charts are analyzed, and statistical graphs and visuals are
posted inside the ICU, to provide an overview of rates
measuring compliance with infection control practices.
This infection control tool is key to enable the ICT and
ICU staff to focus on the necessary strategies for im-
provement of low compliance rates.
Statistical methods
Patients’ characteristics during baseline and during inter-
vention period in each ICU were compared using Fisher’s
exact test for dichotomous variables and unmatched
Student’s t-test for continuous variables. Confidenceintervals (CI) of 95% were calculated using VCStat
(Castiglia). Relative risk (RR) ratios with 95% confidence
intervals (CI) were calculated for comparisons of rates
of CLAB using EPI Info V6. P-values <0.05 by two-sided
tests were considered significant. We conducted two
types of analysis to evaluate the impact of our interven-
tion on CLAB rates. First, we performed an analysis to
compare the data of the first three months (baseline
period) with the remaining pooled months (intervention
period), using RR, 95% CI and P value. Second, in order
to analyze progressive CLAB rate reduction, we used
Poisson regression. We divided the data into the first
three months (baseline period), followed by a nine-
month period (intervention period), and two annual
follow-up periods for the second and third years. We
compared the CLAB rates for each follow-up period
with the baseline CLAB rate. For this comparison, we
used as baseline data only those hospitals that contrib-
uted to follow-up in that period (i.e. excluding from the
baseline hospitals with long lengths of follow-up that
only contributed a shorter length of surveillance). We
used random effects Poisson regression to account for
clustering of CLAB rates within hospitals across time
periods. These models were estimated using Stata 11.0.
For this analysis we used IRR, 95% CI, and P value.Consent
Written informed consent was obtained from the patient
for publication of this report and any accompanying im-
ages. Every hospital’s institutional review board agreed to
the study protocol, and patient confidentiality was
protected by codifying the recorded information, making
it only identifiable to the ICT.Results
Over the whole study period, 4017 adult patients hospi-
talized for 42,749 days in 13 ICUs, from 13 hospitals,
from 8 cities were enrolled, and 26,592 CL-days were
collected. The participating hospitals were summarized
and classified according to number of ICUs and type of
hospital, and ICU characteristics by hospital. The first
ICUs to participate were enrolled in September 2003,
and the most updated data included our analysis dates
from January 2011 (Tables 1 and 2).
Patients’ characteristics, such as age, gender, abdom-
inal surgery, cardiac surgery, trauma, previous infections,
endocrine diseases, chronic obstructive pulmonary dis-
eases, renal impairment, hepatic failure, thoracic surgery,
and stroke were similar during both periods. CL dur-
ation, CL use, and ASIS mean score were higher during
the intervention period. This means patients had higher
intrinsic infection risk at the intervention period
(Table 3).
Table 1 Characteristics of the participating intensive care
units, and hospitals (from September 2003 to January
2011)
Data ICUs, n ICU Patients, n
Type of ICU, n (%)
Cardiac Surgical 1 (8%) 172
Surgical 1 (8%) 222
Medical 2 (15%) 452
Adult Stepdown 2 (15%) 828
Medical Surgical 7 (54%) 2,343
All ICUs 13 (100%) 4,017
Type of hospital, n (%)
Private Community 12 (92%) 3,996
Academic Teaching 1 (8%) 21
All hospitals 13 (100%) 4,017
ICU, Intensive Care Unit.
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tion period, HH compliance improved significantly, as
well as compliance with other measures, including pres-
ence of date on administration set, placed dressing, and
condition of sterile dressing (Table 3).
During the baseline period, we recorded 3,129 CL-days,
for a CL use mean of 0.57. There were 71 CLABs, for an
overall baseline rate of CLAB of 22.7 CLABs per 1000
CL-days (Table 3).
Merging all data of the intervention period, during the
implementation of the multidimensional infection con-
trol approach, we recorded 23,463 CL-days, for a CL use
mean of 0.63, and there were 372 CLABs, for an inci-
dence density of 15.85 CLABs per 1000 CL-days. These
results showed a CLAB rate reduction from baseline byTable 2 Characteristics of the participating intensive care
units by hospital (from September 2003 to January 2011)
Hospital Type of ICU Bed-days, n ICU Beds, n
Hospital 1 Medical 1114 8
Hospital 2 Medical Surgical 353 11
Hospital 3 Medical Surgical 2136 15
Hospital 4 Medical Surgical 7630 24
Hospital 5 Adult Stepdown 6532 16
Hospital 6 Medical Surgical 393 16
Hospital 7 Medical Surgical 7229 8
Hospital 8 Cardiac Surgical 801 11
Hospital 8 Medical 2234 14
Hospital 8 Adult Stepdown 3510 14
Hospital 8 Surgical 1208 11
Hospital 9 Medical Surgical 6113 8
Hospital 10 Medical Surgical 3496 14
ICU, Intensive Care Unit.30% (from 22.7 to 15.85 CLABs per 1000 CL-days; RR 0.70,
95% CI 0.54 – 0.91, P 0.008) (Table 3).
On the other hand, using Poisson regression, we
found a progressive reduction in the rate of CLAB. The
baseline CLAB rate (during the first three months of
study) was progressively reduced during the interven-
tion period to 12.3 CLABs per 1000 CL days, account-
ing for a 43% CLAB rate reduction (IRR 0.57; 95% CI
0.41 – 0.80; P 0.001) (Table 4).
The microorganisms profile is shown in Table 5. The
predominant microorganisms in both periods were
Staphylococcus aureus, coagulase negative Staphylo-
cocci spp. and Acinetobacter spp.
Discussion
If compared with the rates of developed countries, the
baseline rate of CLAB found in this study (22.7 per 1000
CL-days) was more than ten-fold higher than the US 1.1
CLAB rate per 1000 CL-days determined by the CDC/
NSHN [25]; and more than ten-fold higher than the 1.4
CLAB rate determined by KISS [26].
In comparison with global CLAB rates from developing
countries, our CLAB baseline rate was considerably higher
than the fourth international INICC reports published in
2012 (6.8 CLABs per 1000 CL-days) [10]. Likewise, within
the scope of other studies addressing the burden of
CLABs in Turkey, our CLAB rate of our study was
higher than the rate found in other two studies conducted
in Turkey showing 17.6 CLABs per 1000 CL days [4], and
11.8 CLABs per 1000 CL days [27].
In studies performed by INICC member hospitals, it
was shown that the implementation of a multidimen-
sional approach for CLAB--which includes a bundle of
interventions, education, outcome and process sur-
veillance, feedback of CLAB rates, and performance
feedback--resulted in significant reductions in rates of
CLAB in Argentina (46.63 vs. 11.10 CLABs per 1000
CL-days) [28]; in Mexico (46.3 vs. 19.5 CLABs per 1000
CL-days) [29]; in adult ICUs (14.5 vs. 9.7 CLABs per
1000 CL-days) [30]; and in pediatric ICUs (10.7 vs. 5.2
CLABs per 1000 CL-days) [31].
The INICC multidimensional approach for CLAB in-
cluded the following elements. First, the implementation
of an infection prevention bundle based on the guide-
lines published by the SHEA and IDSA [16], which pro-
vide evidence-based recommendations and cost-effective
infection control measures, which can be feasibly adapted
to the ICU setting in developing countries. Second, educa-
tion of HCWs about infection preventive measures. Third,
CLAB outcome surveillance by applying the definitions
for CLAB developed by the U.S. CDC/NHSN [21,22].
Fourth, CLAB process surveillance to monitor compliance
with easily measurable infection control measures, includ-
ing HH performance. Fifth, feedback of CLAB rates. Sixth,
Table 3 Characteristics of patients, hand hygiene compliance, central line care compliance, central line usage, central
line-associated blood stream infection rates, in the baseline period and intervention period
Patients’ characteristics Baseline Intervention RR* 95% CI P- Value
Study period by hospital in months, mean ± SD (range) 3 15.6 ± 9.2 (4 – 36)
Number of Patients 560 3457
*Bed days, n 5517 37232
**No. of CL days, n 3129 23463
***CL use, mean 0.57 0.63 1.1 1.07 – 1.15 0.0001
CL duration, mean ± SD 5.6 ± 9.0 6.8 ± 11.0 - - 0.014
Age, mean ± SD 54.1 ± 22.0 52.3 ± 21.4 - - 0.08
ASIS score, mean ± SD 3.2 ± 1.1 3.6 ± 1.14 - - 0.0001
Male 305 (57%) 2,048 (60%) 1.05 0.91 – 1.21 0.5
Female 230 (43%) 1379 (40%) - - -
Abdominal Surgery, n (%) 58 (10%) 349 (10%) 0.97 0.74 – 1.3 0.84
Cardiac Surgery, n (%) 11 (2%) 72 (2%) 1.1 0.56 – 2.22 0.9
Trauma, n (%) 58 (10%) 357 (10%) 0.99 0.75 – 1.34 0.97
Previous Infections, n (%) 81 (14%) 415 (12%) 0.83 0.653 – 1.1 0.13
Endocrine diseases, n (%) 43 (8%) 250 (7%) 0.94 0.68 – 1.33 0.7
Chronic Obstructive, n (%) 150 (27%) 904 (26%) 0.98 0.82 – 1.17 0.8
Renal Impairment, n (%) 33 (6%) 180 (5%) 0.9 0.61 – 1.3 0.5
Hepatic Failure, n (%) 13 (2%) 50 (1%) 0.62 0.33 – 1.25 0.14
Thoracic Surgery, n (%) 27 (5%) 151 (4%) 0.91 0.6 – 1.42 0.62
Stroke, n (%) 14 (3%) 64 (2%) 0.74 0.4 – 1.43 0.3
Hand Hygiene compliance % (n/n) 32% (427/1328) 49% (5260/10786) 1.52 1.4 – 1.7 0.0001
Date on administration set % (n/n) 33% (1544/4656) 39% (14159/36472) 1.17 1.11 – 1.2 0.0001
Placed sterile dressing % (n/n) 78% (3617/4656) 90% (32895/36472) 1.2 1.12 – 1.2 0.0001
Correct condition of dressing % (n/n) 76% (3537/4656) 73% (26699/36472) 0.96 0.93 – 0.99 0.04
No. of CLAB, n 71 372
CLAB Rate per 1000 CL days 22.7 15.85 0.7 0.54 – 0.91 0.008
SD, standard deviation; CL, central line; CLAB, Central line associated bloodstream infection; RR, relative risk; CI, confidence interval; ASIS, average severity of
illness score.
*Bed-days are the total number of days that patients are in the ICU during the selected time period.
**CL-days: the total number of days of exposure to central line by all of the patients in the selected population during the selected time period.
***CL use ratios were calculated by dividing the total number of CL-days by the total number of bed-days.
Table 4 Central line associated blood stream infection rates stratified by the length of time that each intensive care









Crude CLAB rate/1000 CL
days
IRR accounting for clustering by
ICU
P value
1-3 months (baseline) 13 3,129 71 22.7 1 -
4-12 months 13 9,751 170 17.4 0.79 (0.59 – 1.04) 0.103
Second year 11 7,287 123 16.9 0.63 (0.46 – 0.87) 0.004
Third year 6 6,425 79 12.3 0.53 (0.38 – 0.76) 0.001
Poisson regression.
INICC, International Nosocomial Infection Control Consortium; ICU, intensive care unit; CL, central line; CLAB, Central line associated bloodstream infection; IRR,
incidence-rate ratio.
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Table 5 Microorganism related to central line associated
blood stream infection in adult intensive care units in
phase 1 (baseline period) and phase 2 (intervention
period)
Isolated Microorganisms Baseline Intervention P.value
Acinetobacter spp. % (n) 14.5% (9) 23.2% (79) 0.1293
Candida spp. % (n) 9.7% (6) 8.2% (28) 0.7023
Citrobacter spp. % (n) 0.0% (0) 0.3% (1) -
Corynobacter % (n) 0.0% (0) 0.6% (2) -
E. Coli spp. % (n) 6.5% (4) 6.2% (21) 0.8429
Enterobacter spp. % (n) 6.5% (4) 3.5% (12) 0.4627
Enterococcus spp. % (n) 3.2% (2) 6.7% (23) 0.441
Haemophilius, spp. 0.0% (0) 0.6% (2) -
Klebsiella spp. % (n) 3.2% (2) 6.2% (21) 0.5365
Proteus spp. % (n) 0.0% (0) 0.3% (1) -
Pseudomonas spp. % (n) 8.1% (5) 10.9% (37) 0.5089
Staphylococcus aureus spp. % (n) 21.0% (13) 17.0% (58) 0.4516
Coagulase-negative
staphylococci spp. % (n)
27.4% (17) 15.0% (51) 0.0159
Serratia spp. % (n) 0.0% (0) 0.6% (2) -
Stenotrophomonas % (n) 0.0% (0) 0.3% (1) -
Streptococcus % (n) 0.0% (0) 0.6% (2) -
Total 100% (62) 100% (341) -
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by reviewing and discussing charts results at monthly in-
fection control meetings.
In our study, patients’ characteristics, such as age, gen-
der, and underlying diseases showed similar patient in-
trinsic risk in both study periods. But ASIS score, CL
use, and CL duration were higher during the interven-
tion period, meaning that the patient intrinsic risks were
higher in the intervention period. During the implemen-
tation of the INICC multidimensional approach, we
found an improvement in process surveillance rates,
with HH compliance improved by 52%, compliance with
date on administration set improved by 17%, compliance
with placed sterile dressing improved by 20%, and com-
pliance with correct condition of dressing was high dur-
ing both periods. During the study period, the high
CLAB rate at baseline was reduced from 22.7 to 12.00
per 1000 CL-days, showing a 39% CLAB rate reduction
and evidencing the effectiveness of the applied multidi-
mensional approach.
Our study can be compared with an earlier bundle study
[15], and a number of important differences between them
can be mentioned. First, this previously published bundle
included five elements. In contrast, we included eleven.
Second, compliance was not measured for any of the
bundle components, whereas we checked compliance of
5 bundle components. Third, characteristics of patientsduring baseline and intervention periods were not col-
lected nor analyzed so as to check and compare such indi-
vidual features, whereas we did and could find that our
patients were statistically similar during both periods.
Fourth, the follow-up period was 18 months, whereas we
included a 36-month follow-up period. Fifth, intervention
included only a bundle and a check list, whereas our study
included the above-mentioned 6 simultaneous interven-
tions. Finally, microorganisms responsible for CLAB were
not provided, whereas in our study we included the CLAB
microorganism profile for both baseline and intervention
periods. The most important differences were measure-
ments of the population’s features and compliance with
bundle elements, which allowed us to analyze the real
impact of our intervention by excluding confounders
associated with patients’ characteristics and infection
control practices.
Regarding the microorganisms profile, we identified a
predominance Staphylococcus aureus, coagulase-negative
staphylococci spp. and Acinetobacter spp. during both pe-
riods, which is similar to the findings of other studies
conducted in limited-resource countries [7-10].
This study has several limitations. First, our findings
cannot be generalized to all ICU patients from Turkey.
However, this study proved that a multidimensional ap-
proach is fundamental to understand and fight against the
adverse effects of CLAB in the ICU setting of Turkey. Sec-
ond, the setting of three-month baseline period may be
short and might have overestimated the effect of the inter-
vention; however, during baseline period the sample size
was good enough, and the confidence intervals for the
baseline rate were narrow. Finally, because we did not
count on the necessary resources, we were not able to dif-
ferentiate between early and late onset infections; we
could not quantify in detail all the interventions included
in our multidimensional approach, such as education; and
we could not quantify compliance with some of the com-
ponents of our bundle. Therefore, we could not evaluate
the components’ individual implications or other context-
ual factors related to the ICU or hospitals individually.
Nevertheless, our main goal was to reduce the high base-
line CLAB rates found in our ICU, and although our
interventions were inexpensive, the individual evaluation
would have required more allocation of time, contributing
to unnecessary harm for ICU patients. Fortunately, as
from January 2012, we have been able to collect all these
process surveillance data.
Conclusions
This is the first multicenter study to report a substantial
reduction in CLAB rates in the ICU setting of Turkey,
proving this kind of infection control approach success-
ful. Despite higher patient intrinsic risk characteristics
during the intervention period, a multidimensional
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ive measures for CLAB resulted in significant reduc-
tions in the CLAB incidence rate. Nevertheless, it is
worth highlighting that the reduction in CLAB rates
does not derive from surveillance itself. These systemat-
ically collected data should serve to guide ICPs in their
strategies for improvement of patient care practices,
such as performance feedback, as demonstrated in sev-
eral previous studies conducted in limited resources
countries [29,30,32,33].
We expect that these preventive strategies proven ef-
fective in the INICC AICUs of Turkey by means of the
implementation of the multidimensional approach for
CLAB prevention results in a wider acceptance of infec-
tion control programs in hospitals worldwide, leading to
significant CLAB reductions. Through the INICC net-
work, investigators are freely furnished with training and
methodological tools to perform outcome and process
surveillance, and to implement an effective infection
prevention model for CLABs, and at the same time, the
publication of these findings serves to foster relevant sci-
entific evidence-based literature. For this reason, every
hospital is invited to participate in the INICC project,
which was set up to respond to the compelling need in
the developing world to significantly prevent, control
and reduce CLABs and their adverse effects.
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